Defining novel mechanisms of clonal emergence in Group A Streptococcus

定义 A 组链球菌克隆出现的新机制

基本信息

项目摘要

PROJECT SUMMARY The emergence and spread of closely related strains or clones are characteristic of many bacteria causing serious disease in humans. The major human pathogen group A Streptococcus (GAS) displays such behavior and has long been a model organism for studying clonal emergence in bacteria. GAS is divided into emm types based on variation in the emm gene which encodes for the cell-surface, anti-phagocytic M protein. The present paradigm is that GAS clonal emergence occurs due to genetic recombination events which either allow for acquisition of a novel virulence factor or for increased production of existing virulence factors, particularly those encoded by the nga-slo operon. By sequencing >1,000 emm4 strains from diverse temporal and geographic sources, we have identified that a new emm4 clone has replaced previously circulating emm4 strains over the past decade. The “emergent” strains have not undergone significant genetic recombination, do not contain new virulence factor encoding genes, and have significantly lower transcript levels of the nga-slo operon relative to the “replaced” strains. However, emergent emm4 GAS are more virulent than replaced emm4 strains in both animal models and during growth in human blood. Thus, this newly identified clonal emergence does not fit the current understanding of GAS clonal emergence. It is the goal of this R21 proposal to begin to establish novel mechanisms underlying the proliferation of emergent emm4 GAS. In specific aim 1, we will determine whether emergent emm4 strains have increased colonization/transmission capacities relative to replaced strains. This aim will employ both primary human cells as well as a newly established animal model of GAS transmission. In specific aim 2, we will leverage our existing transcriptomic data which show that emergent strains have significantly higher transcript levels of genes encoding proteins putatively involved in cell surface oxidative stress response and peptidoglycan turnover. We will determine whether the emergent GAS strains have augmented resistance to oxidative stress and to challenge by human neutrophils, which utilize reactive oxygen species as a major killing mechanism. Moreover, cell wall differences between emergent and replaced strains will be explored using complementary imaging techniques and by testing susceptibility to cell-envelope active innate antimicrobials. The specific role of particular genes in observed phenotypic differences will be assessed using either an insertional mutagenesis approach or by modifying gene expression when the candidate genes are essential. These studies have been devised to facilitate the subsequent design and execution of downstream investigations of the molecular underpinning of bacterial epidemics, a key aspect of pathogenesis for a wide variety of medically important pathogens.
项目摘要 密切相关的菌株或克隆的出现和传播是许多细菌引起的特征。 严重的人类疾病。主要的人类病原体A组链球菌(GAS)表现出这种行为 并且长期以来一直是研究细菌克隆出现的模式生物。GAS分为EMM类型 基于编码细胞表面抗吞噬M蛋白的emm基因的变异。本 范式是GAS克隆出现是由于遗传重组事件发生的, 获得新的毒力因子或增加现有毒力因子的产量,特别是那些 由NGA操纵子编码。通过对来自不同时间和地理的> 1,000个emm 4菌株进行测序, 来源,我们已经确定,一个新的emm 4克隆已取代以前循环emm 4菌株在 过去十年“新出现的”菌株没有发生显著的基因重组,不含新的 毒力因子编码基因,并且相对于 被“取代”的品种。然而,在两个菌株中,新出现的emm 4 GAS比替代的emm 4菌株毒力更强。 动物模型和在人血液中生长期间。因此,这种新发现的克隆出现不符合 目前对GAS克隆出现的了解。R21提案的目标是开始建立新的 emm 4 GAS增殖的潜在机制。在具体目标1中,我们将确定 新出现的EMM 4菌株相对于替代菌株具有增加的定殖/传播能力。这 aim将使用原代人类细胞以及新建立的GAS传播动物模型。在 具体目标2,我们将利用我们现有的转录组学数据,这些数据表明新出现的菌株具有 编码参与细胞表面氧化应激的蛋白质的基因的转录水平显著更高 反应和肽聚糖周转。我们将确定新出现的GAS菌株是否增加了 抗氧化应激和人类嗜中性粒细胞的挑战,利用活性氧作为一种抗氧化剂。 主要的杀人机制此外,将探讨新出现的菌株和替代菌株之间的细胞壁差异 使用互补成像技术和通过测试对细胞包膜活性先天性 抗菌剂特定基因在观察到的表型差异中的特定作用将使用以下方法进行评估: 插入诱变方法或通过修饰基因表达, 具有本质意义设计这些研究是为了促进下游的后续设计和执行。 细菌流行病的分子基础的调查,广泛的发病机制的一个关键方面, 多种医学上重要的病原体。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The Indirect Impact of the SARS-CoV-2 Pandemic on Invasive Group a Streptococcus, Streptococcus Pneumoniae and Staphylococcus Aureus Infections in Houston Area Children.
Invasive Group A Streptococcus in Infants Less Than 1-year of Age From 2012 to 2022: A Single-Center Experience.
2012 年至 2022 年 1 岁以下婴儿的侵袭性 A 组链球菌:单中心经验。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anthony Richard Flores其他文献

Anthony Richard Flores的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Anthony Richard Flores', 18)}}的其他基金

Evolution and pathogenesis of serotype V group B Streptococcus in humans
人类血清型 B 型链球菌的进化和发病机制
  • 批准号:
    10355538
  • 财政年份:
    2021
  • 资助金额:
    $ 19.88万
  • 项目类别:
Defining novel mechanisms of clonal emergence in Group A Streptococcus
定义 A 组链球菌克隆出现的新机制
  • 批准号:
    10189994
  • 财政年份:
    2021
  • 资助金额:
    $ 19.88万
  • 项目类别:
Evolution and pathogenesis of serotype V group B Streptococcus in humans
人类血清型 B 型链球菌的进化和发病机制
  • 批准号:
    10217675
  • 财政年份:
    2021
  • 资助金额:
    $ 19.88万
  • 项目类别:
Texas Medical Center Training Program in Antimicrobial Resistance
德克萨斯医学中心抗菌素耐药性培训计划
  • 批准号:
    10401444
  • 财政年份:
    2019
  • 资助金额:
    $ 19.88万
  • 项目类别:
Texas Medical Center Training Program in Antimicrobial Resistance
德克萨斯医学中心抗菌素耐药性培训计划
  • 批准号:
    10621908
  • 财政年份:
    2019
  • 资助金额:
    $ 19.88万
  • 项目类别:
Texas Medical Center Training Program in Antimicrobial Resistance
德克萨斯医学中心抗菌素耐药性培训计划
  • 批准号:
    10160768
  • 财政年份:
    2019
  • 资助金额:
    $ 19.88万
  • 项目类别:
Contribution of LiaFSR to pathogenesis and carriage of group A Streptococcus
LiaFSR 对 A 族链球菌发病机制和携带的贡献
  • 批准号:
    9605689
  • 财政年份:
    2017
  • 资助金额:
    $ 19.88万
  • 项目类别:
Contribution of LiaFSR to pathogenesis and carriage of group A Streptococcus
LiaFSR 对 A 族链球菌发病机制和携带的贡献
  • 批准号:
    10082424
  • 财政年份:
    2017
  • 资助金额:
    $ 19.88万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 19.88万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 19.88万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 19.88万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 19.88万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 19.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 19.88万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 19.88万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 19.88万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 19.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 19.88万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了